Intravitreal (IVT) Injectable Market
Intravitreal (IVT) Injectable Market Study by Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, and Antifungal for Diabetic Retinopathy, Macular Degeneration, and Others from 2024 to 2034
Analysis of Intravitreal (IVT) Injectable Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Intravitreal (IVT) Injectable Market Outlook
The intravitreal (IVT) injectable market size is expected to be valued at US$ 17,565.4 million in 2024. Sales of intravitreal (IVT) injectables are projected to rise at a CAGR of 4.2% from 2024 to 2034. The market is expected to be worth US$ 26,526.1 million by 2034.
The demand for intravitreal injectables is growing due to advancements in pharmaceutical delivery technologies and an increase in the prevalence of eye disorders. The aging population and the growing desire for low-risk, effective treatment options are fueling the intravitreal (IVT) injectable market expansion.
The development of sustained-release implants, biodegradable microspheres, and intelligent drug delivery systems are stimulating growth in the intravitreal (IVT) injectable market. These advancements are intended to increase medication efficacy, decrease injection frequency, and improve patient compliance.
Advancements in targeted therapies and personalized medicine, which enable accurate and efficient treatment of eye ailments, are further contributing to the market’s growth. Increased research and development efforts to investigate novel treatment alternatives and broaden the indications for IVT injectables are also adding up to the increasing market value.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 17,565.4 million |
| Forecasted Market Value (2034F) | US$ 26,526.1 million |
| Global Market Growth Rate (2024 to 2034) | 4.2% |
| Corticosteroids Segment Growth Rate (2024 to 2034) | 5.1% |
| Retinal Vein Occlusions Segment Growth Rate (2024 to 2034) | 4.7% |
| North America Market Share (2024) | 3.4% |
| East Asia Market Share (2024) | 6.6% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Facets are Catalyzing the Growth of the Intravitreal Injectable Industry?
“Development of Targeted Therapies and Personalized Medicines”
The development of sustained-release implants, biodegradable microspheres, and smart drug delivery systems are contributing to the growth of the market. These advancements are responsible for increasing medication efficacy, decreasing injection frequency, and improving patient compliance.
The development of targeted therapies and personalized medicine and the adoption of combination therapies are fueling the demand for intravitreal injectables. Rising Focus on research and development to investigate novel treatment alternatives are bolstering the market’s growth.
What are the Factors Inhibiting Growth in the Intravitreal Injection Market?
“High Cost of Intravitreal Injectables Restricting Market Growth”
The clinical trials and research and development related to intravitreal injectables are costly and resource-intensive. High development expenditures are a significant obstacle that inhibits many intravitreal (IVT) injectable vendors from introducing novel items to the market. The adoption of intravitreal injectables can be affected by adverse effects or safety issues.
The market demand can be severely affected by limited insurance coverage and reimbursement restrictions. This is expected to hinder the market as patients and healthcare providers struggle to secure coverage for these treatments.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
The intravitreal (IVT) injectable market in North America is expected to increase at a CAGR of 3.4% until 2034. The primary catalyst of the spike is the increased demand for IVT injectables in major markets, particularly the United States and Canada. By 2034, the United States is set to command the leading share of 92.4% of the regional market.
The IVT injectable market in East Asia is expected to develop at a robust CAGR of 6.6% through 2034. China is the most lucrative market in East Asia, accounting for a share of 47.9%. The growing significance and geographic diversity of the market are expected to generate significant opportunities for established players and new entrants.
What is Fueling Demand for Intravitreal (IVT) Injectables in North America?
“Growing Prevalence of Retinal Disorders in North America”
An aging population and an increase in the prevalence of retinal diseases are the main factors influencing the United States' intravitreal (IVT) injectable market expansion. The flourishing market demand is attributed to the rising use of cutting-edge treatment alternatives and a robust healthcare system.
Patient awareness campaigns and educational initiatives propel the demand for intravitreal therapy, which is crucial in prompt diagnosis and intervention. In 2024, the United States is expected to attain a 93.3% market share.
| Attributes | Details |
|---|---|
| United States Market CAGR | 3.3% |
| United States Market Size (2024) | US$ 9,663 million |
| Canada Market CAGR | 4.4% |
| Canada Market Size (2024) | US$ 510 million |
Age-related macular degeneration (AMD) is becoming common in Canada, contributing to the market expansion. Raising awareness through public health initiatives and highlighting early detection and routine eye examination results in a proactive approach to retinal health, driving the market in Canada. In 2024, Canada is expected to secure a 4.9% market share.
Which Aspects are Influencing the Asia Pacific Intravitreal (IVT) Injectable Market?
“Rising AMD and Diabetic Retinopathy Cases in Asia Pacific”
Diabetic retinopathy has become prevalent in the rising aging population of China, which is contributing to the growth of the market for efficient retinal treatments. In China, telemedicine usage and digital health initiatives are improving, increasing patient education and involvement, which is critical for early diagnosis and prompt treatment of retinal problems. China is expected to acquire a market share of 47.4% in 2024.
| Attributes | Details |
|---|---|
| China Market CAGR | 6.7% |
| China Market Size (2024) | US$ 790 million |
| Japan Market CAGR | 6.6% |
| Japan Market Size (2024) | US$ 578 million |
The market in Japan is stimulated by a rapidly aging population and a high prevalence of age-related macular degeneration (AMD), which has created an enormous demand for novel and effective retinal treatments. The adoption of intravitreal injectables is influenced by the incorporation of artificial intelligence and data analytics into Japan's healthcare system, which is helping to facilitate early diagnosis and customized treatment plans for retinal illnesses. Japan is expected to garner a market share of 34.7% in 2024.
Category-wise Outlook
According to the drug class, the anti-VEGF segment is projected to account for 87.6% of the market share. The macular degeneration segment of the indication category is set to dominate the market with a 31.5% share. The diabetic retinopathy segment is expected to hold a share of 30.3% of the market.
The hospital pharmacies segment is poised to have a dominant share of 35.6% of the market based on distribution channels. The retail pharmacies segment is expected to achieve a 24% market share.
Which Drug Class is Leading the Intravitreal Injectable Market?
“Anti-VEGF Segment's Widespread Adoption in Retinal Care”
| Anti-VEGF | Details |
|---|---|
| Market Size (2024) | US$ 15,417.4 million |
| Market Share (2024) | 87.8% |
The rising incidence of retinal disorders and the established therapeutic benefits of anti-VEGF drugs drive the market forward. In 2024, the anti-VEGF segment is expected to account for 87.8% of the intravitreal (IVT) injectable market by drug class. Since anti-VEGF medications effectively treat neovascular illnesses by preventing aberrant blood vessel formation in the eye, they hold a dominant share in the intravitreal injectable market.
What is Propelling Sales of Intravitreal Injectables for Treating Macular Degeneration?
“Clinical Efficacy and Established Treatment Protocols Favor Adoption of IVT Injectables”
| Macular Degeneration | Details |
|---|---|
| Market Size (2024) | US$ 5,818.3 million |
| Market Share (2024) | 33.1% |
The growing trend of developing treatments for age-related ocular illnesses is consistent with the increased adoption of IVT injectables in treating macular degeneration. The market is placing more emphasis on this indication due to the growing global burden of vision impairment linked to macular degeneration.
In 2024, the macular degeneration segment is expected to capture 33.1% of the intravitreal (IVT) injectable market by indication. IVT injectables are rising in demand for the treatment of macular degeneration due to improved awareness and early diagnosis.
What Makes Hospital Pharmacies the Frontrunner in the IVT Injectable Market?
“Hospitals Provide Sterile Environments Crucial for Intravitreal Drug Handling.”
| Hospital Pharmacies | Details |
|---|---|
| Market Size (2024) | US$ 6,326.3 million |
| Market Share (2024) | 36.0% |
Hospital pharmacies are recommended for providing intravitreal injections since patients who receive them frequently need close monitoring and prompt medical intervention. The demand for intravitreal injectables is expected to increase because hospital pharmacies are staffed by skilled healthcare personnel capable of managing their complexities.
In 2024, hospital pharmacies are expected to account for 36% of the market share, based on the distribution channel. Hospitals can quickly handle crises and adverse reactions, protecting patients during treatment processes.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Analysis
The market for intravitreal (IVT) injectables is characterized by fierce competition among significant firms attempting to meet the increasing need for novel therapies for various ocular ailments. Leading intravitreal injectable providers and promising startups are actively engaged in research and development to launch innovative IVT injectables.
The rising prevalence of age-related macular degeneration and retinal diseases is stimulating the market. Regulatory approvals, safety profiles, and effectiveness are essential elements that impact competition.
The intravitreal (IVT) injectable manufacturers are looking to increase their market share. They are focusing on partnerships, collaborations, and strategic acquisitions as essential strategies. The dynamic landscape is influenced by ongoing technological breakthroughs and a focus on patient-centric solutions.
Notable Advancements
- In October 2021, Bausch + Lomb and Clearside Biomedical, Inc. introduced XIPERE, a suprachoroidal solution containing triamcinolone acetonide, which has received FDA approval for the treatment of macular edema associated with uveitis.
- In July 2018, Roche announced the first-ever successful phase II research results of a long-acting delivery device to treat neovascular age-related macular degeneration (AMD).
- The United States Food and Drug Administration (FDA) authorized Regeneron Pharmaceuticals, Inc.'s EYLEA® (aflibercept) Injection in August 2018.
Segmentation of Intravitreal (IVT) Injectable Market Research
-
By Drug Class :
- Anti-VEGF
- Corticosteroids
- Antibiotics
- Antivirals
- Antifungal
-
By Indication :
- Diabetic Retinopathy
- Macular Degeneration
- Endophthalmitis
- Retinal Vein Occlusions
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Others
-
By Region :
- North America
- East Asia
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Middle East and Africa
- FAQs -
What was the Value of the IVT Injectable Market in 2019?
The global intravitreal injectable market was worth US$ 13,950.1 million in 2019.
What is the Sales Outlook for Intravitreal (IVT) Injectables in 2024?
The sales of intravitreal (IVT) injectables are likely to be valued at US$ 17,565.4 million in 2024.
What is the Demand Forecast for IVT Injectables by 2034?
The demand for intravitreal (IVT) injectables is projected to reach a market value of US$ 26,526.1 million by 2034.
What is the Growth Projection for the Intravitreal (IVT) Injectable Market?
The adoption of intravitreal (IVT) injectables is projected to rise at a CAGR of 4.2% from 2024 to 2034.
At What CAGR is the IVT Injectable Market in North America Predicted to Develop?
The North American intravitreal injectable market is forecasted to expand at a CAGR of 3.4% from 2024 to 2034.
At What CAGR is the Intravitreal (IVT) Injectable Market in East Asia Predicted to Grow?
The East Asia intravitreal injectable market is forecasted to expand at a CAGR of 6.6% through 2034.
Intravitreal (IVT) Injectable Market
*Mail attachment includes 144 figures & 48 tables